Abstract
Inflammatory bowel disease (IBD) belongs to a group of chronic diseases that includes Crohn's disease and ulcerative colitis. The purpose of the work was to analyze scientific data on the history of the creation, use and effectiveness of genetically engineered biological drugs (GEBD) in the treatment of IBD. We examined Russian and foreign sources on the use of GEBD for the treatment of IBD, presented in scientific electronic libraries and in the information system for doctors in 2018-2023. The goal of IBD therapy is to achieve and maintain long-term clinical and endoscopic remission. However, a significant proportion of patients are resistant to basic drugs, and therefore require the use of new pharmacological agents. The use of GEBD can improve the condition of patients who have not sufficiently responded to basic therapy. This review examines the main groups of biological drugs currently available in Russia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
